Enovis is caught in a confirmed technical downtrend — death cross in place, below all major moving averages, with 18% short interest — yet simultaneously trades at a forward P/E of 5.2x with analysts projecting 78% upside to their consensus target of $37.41 and a four-quarter perfect beat streak; the fundamental and technical pictures are sharply at odds, making patience for a technical confirmation essential before acting on the value case.
Thesis pillars
- Extreme Valuation Dislocation From Analyst Consensus→Stable
- Confirmed Downtrend Blocks Near Term Entry↓Deteriorating
- Perfect Four Quarter Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026
Enovis Corporation (ENOV) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $21.91: Risk below floor (2.5 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 4.47; Below-average business quality.
Enovis Corporation is a medical technology company that develops, manufactures, and distributes medical devices for reconstructive surgery, rehabilitation, pain management, and physical therapy, organized into Prevention & Recovery and Reconstructive segments. The company... Read more
Sell if holding. Engine safety override at $21.91: Risk below floor (2.5 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 4.47; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 85. Score 6.1/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.
About Enovis Corporation
About Enovis Corporation
Enovis Corporation operates through two segments — Prevention & Recovery, generating approximately 67% of its revenue in the U.S., and Reconstructive, generating approximately 48% of its revenue in the U.S. — with approximately 42% of total 2025 net sales derived from operations outside the United States, mostly in Europe. The company completed seven acquisitions in 2025, four within Reconstructive and three within Prevention & Recovery.
Enovis's Prevention & Recovery segment sells rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems, and electrical stimulation products used by orthopedic specialists, physical therapists, and athletic trainers, competing against Össur and Breg. Its Reconstructive segment develops implants, instrumentation, and enabling technologies for shoulder, hip, knee, and extremity joint replacement and fixation, competing against much larger rivals including Stryker, Zimmer Biomet, and DePuy Synthes. The company sources cobalt-chromium, stainless-steel, and titanium alloys plus ultra-high-molecular-weight polyethylene for its Recon implants and foam ethylene-vinyl-acetate copolymer for its P&R bracing products, generally using more than one supplier per material to mitigate shortage risk. Enovis's growth strategy relies heavily on acquisitions, financed in part through a term loan, revolving credit facility, and convertible 2028 Notes.
Show full overview
Enovis's acquisition-driven growth has come with material goodwill-impairment risk: the company recognized non-cash goodwill impairment charges of $501.0 million in the fourth quarter of 2025 and $540.8 million in the third quarter of 2025 — split between its Prevention & Recovery and Reconstructive reporting units and triggered by a sustained decline in Enovis's stock price and market capitalization relative to those units' carrying values — following a $645.0 million impairment charge in 2024. Should Enovis's share price remain depressed or reporting-unit performance weaken further, the 10-K warns additional non-cash charges of this scale remain possible.
See also: Healthcare · Medical Devices
From Enovis Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Enovis Corporation
Latest news
- NEWS Enovis (ENOV) Faces A Tougher Outlook On Sales Pressure And Undervalued Narrative - Yahoo Finance — Yahoo Finance positive
- NEWS Enovis (ENOV) Faces A Tougher Outlook On Sales Pressure And Undervalued Narrative - finance.yahoo.com — finance.yahoo.com positive
- NEWS Enovis Corp (ENOV) Valuation: PE, PB & Fair Value Analysis - TradingKey — TradingKey neutral
- NEWS Enovis Corp (ENOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS Enovis Corp (ENOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com — tradingkey.com neutral
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicinternational operations (outside U.S.)42%10-K Item 1: 'approximately 42% of our Net sales were derived from operations outside the U.S., the majority of which is in Europe with the remaining portion mostly in the Asia-Pacific region.'
Material Events(8-K, last 90d)
- 2026-05-19Item 5.02LOWAt Enovis's May 19, 2026 Annual Meeting, stockholders approved an amendment to the 2020 Omnibus Incentive Plan authorizing an additional 3,650,000 shares for issuance and raising the annual outside-director compensation cap from $350,000 to $750,000; no director or officer departure was disclosed.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.91: Risk below floor (2.5 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 4.47; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 85. Prior stop was $20.38. Score 6.1/10, moderate confidence.
Analyst target: $31.39 (+43.3% upside). Prior stop was $20.38. Stop-loss: $20.38.
Risk below floor (2.5 < 2.5).
Enovis Corporation trades at a P/E of N/A (forward 6.2). TrendMatrix value score: 9.3/10. Verdict: Sell.
19 analysts cover ENOV with a consensus score of 4.2/5. Average price target: $36.
What does Enovis Corporation do?Enovis Corporation is a medical technology company that develops, manufactures, and distributes medical devices for...
Enovis Corporation is a medical technology company that develops, manufactures, and distributes medical devices for reconstructive surgery, rehabilitation, pain management, and physical therapy, organized into Prevention & Recovery and Reconstructive segments. The company generates revenue through independent distributors and direct sales to orthopedic specialists and healthcare professionals worldwide, with approximately 42% of 2025 net sales derived from operations outside the United States, primarily in Europe.